Despite of the limited number of cases, the contrasting mechanisms of these mutations—TP53ms resulting in loss of tumor suppression and genomic instability, and PPM1Dms partially suppressing p53 while maintaining some DNA damage response function, allowing survival under genotoxic stress with a stable, low clonal burden—likely contribute to the observed clinical outcomes. This evidence concerns the gene TP53 and neoplasm.